within Pharmacolibrary.Drugs.ATC.L;

model L03AB16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Peginterferon alfacon-2 is a synthetic, pegylated form of interferon alpha used as an antiviral and immunomodulatory agent, primarily developed for the treatment of chronic hepatitis C infection. Its clinical use has largely been replaced by direct acting antivirals, but it was previously approved as part of combination therapy for hepatitis C.</p><h4>Pharmacokinetics</h4><p>No published literature reporting specific pharmacokinetic parameters such as clearance, volume of distribution, or absorption rate constants for peginterferon alfacon-2 in humans could be identified. Approximate estimates have been suggested based on available information for similar pegylated interferons.</p><h4>References</h4><ol><li><p>Hu, X, et al., &amp; Werneburg, B (2016). COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. <i>British journal of clinical pharmacology</i> 82(2) 380–388. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12968&quot;>10.1111/bcp.12968</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27060836/&quot;>https://pubmed.ncbi.nlm.nih.gov/27060836</a></p></li><li><p>Simó, M, &amp; Iljicsov, A (2017). [Role of peginterferon-β-1a in the therapy of multiplex sclerosis]. <i>Ideggyogyaszati szemle</i> 70(11-12) 365–368. DOI:<a href=&quot;https://doi.org/10.18071/isz.70.0365&quot;>10.18071/isz.70.0365</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29870644/&quot;>https://pubmed.ncbi.nlm.nih.gov/29870644</a></p></li><li><p>Zhao, Y, et al., &amp; Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. <i>Med (New York, N.Y.)</i> 3(9) 612–621.e3. DOI:<a href=&quot;https://doi.org/10.1016/j.medj.2022.06.006&quot;>10.1016/j.medj.2022.06.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35853458/&quot;>https://pubmed.ncbi.nlm.nih.gov/35853458</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB16;
